Broader Transparency on Risk-benefit Assessment of the Bial Trial in France
William Wei Lim Chin · Journal of Advances in Medicine and Medical Research · 2016
On 11 January 2016, a Phase I trial of an experimental fatty acid amide hydrolase inhibitor for pain developed by Bial-Portela was halted after six healthy volunteers were admitted to the University of Rennes Hospital in France. One volunteer died and four suffered severe neurolo...
Open access
Research Article
10.9734/BJMMR/2016/26077